AsthmaEAPT2NCT07006285
T2 Biomarkers Predictive Value in Occupational Asthma After Cessation of Exposure.
A study testing Measure of T2 biomarkers in people with Asthma and Occupational Asthma, run by University Hospital, Strasbourg, France at 1 site in France.
Trial summary
Occupational exposure is known to cause 15% of asthma cases. The main treatment for occupational asthma is to stop exposure if possible. Although, remission of occupational asthma only occurs in only 30 % of patients after cessation of exposure. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Asthma, Occupational Asthma, Occupational Diseases
- What is being tested?
- Measure of T2 biomarkers
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- 1 siteFrance
- Study dates
- Jun 2025to Jun 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age over 18
- Diagnosis of occupational asthma by specific inhalation challenge
- Exposure to sensitizing agent avoided or reduced
- Able to understand the aims and risks of the research and to give free and informed consent
- For women of childbearing age: effective contraception in progress.
- Benefiting from social security coverage
Who cannot join
- Impossibility of giving the subject informed information (subject in emergency situation, difficulties in understanding the subject)
- Subject under court protection
- Subject under guardianship or curatorship
- Pregnant or breast-feeding patient
Trial locations and contacts
1 site in 1 country.
About this study
Occupational exposure is known to cause 15% of asthma cases. The main treatment for occupational asthma is to stop exposure if possible. Although, remission of occupational asthma only occurs in only 30 % of patients after cessation of exposure. There is currently no way of predicting which patients will go into remission after cessation of exposure.
In non-occupational asthma, the inflammatory biomarker T2 has allowed the entry into personalized medicine and can predict future exacerbations.
Read more
The investigators hypothesize that T2 biomarkers could be predictive markers for remission in occupational asthma after exposure cessation.
The investigators intend to carry out a follow-up study at the University Hospital of Strasbourg to perform the non-specific bronchial hyperresponsiveness test to assess remission in patients diagnosed with occupational asthma and to compare baseline T2 biomarkers in remission and non remission patients.
- Conditions
- Asthma, Occupational Asthma, Occupational Diseases
- Being tested
- Measure of T2 biomarkers
- Medical subject headings
- Asthma, Asthma, Occupational, Occupational Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Measure of T2 biomarkersOther
T2 Biomarkers are estimated via induced sputum:
Sputum is induced through increasing concentrations from 0.9 or 3% to 4% and 5% of hypertonic solution.
Assessment of nonspecific bronchial hyperresponsiveness is realized by metacholine challenge
| Study group | Role | What they receive |
|---|---|---|
| patients with occupational asthma | Other | Not described Receives: Other: Measure of T2 biomarkers |
What is being measured
The primary outcome is the main question the study is designed to answer.
Remission of occupational asthma
Remission of occupational asthma is defined by absence of nonspecific bronchial hyperresponsiveness.
Assessment of nonspecific bronchial hyperresponsiveness is realized by metacholine challenge
Measured: Day 1
Comparison of TH2-type inflammation levels
To compare the level of Th2-type inflammation in sputum from patients in remission versus patients with persistent asthma.
Measured: Day 1
Secondary outcomes (1)
Remission of occupational rhinitis
Remission of occupational rhinitis is assessed by symptom score
Measured: Day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Jun 2025
- Study startJun 2025 (estimated)
- Primary completionJun 2025 (estimated)
- Study completionJun 2026 (estimated)
Why it stopped: Because of the negative results reported in other studies
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AsthmaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Strasbourg, France
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07006285
- Sponsor's protocol ID
- 9224
- Acronym
- EAPT2
- Status last verified
- Jun 2026
- First submitted
- 8 Nov 2024
- Last updated
- 23 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- T2 Biomarkers Predictive Value in Occupational Asthma After Cessation of Exposure.
- ClinicalTrials.gov ID
- NCT07006285
- Acronym / sponsor ID
- EAPT2 / 9224
- Conditions
- Asthma, Occupational Asthma, Occupational Diseases
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: Because of the negative results reported in other studies
- Enrolment
- 0 participants (actual)
- Lead sponsor
- University Hospital, Strasbourg, FranceUniversity, hospital or other
- Study start
- Jun 2025 (estimated)
- Primary completion
- Jun 2025 (estimated)
- Study completion
- Jun 2026 (estimated)
- First posted
- 5 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Occupational exposure is known to cause 15% of asthma cases. The main treatment for occupational asthma is to stop exposure if possible. Although, remission of occupational asthma only occurs in only 30 % of patients after cessation of exposure. There is currently no way of predicting which patients will go into remission after cessation of exposure.
In non-occupational asthma, the inflammatory biomarker T2 has allowed the entry into personalized medicine and can predict future exacerbations.
The investigators hypothesize that T2 biomarkers could be predictive markers for remission in occupational asthma after exposure cessation.
The investigators intend to carry out a follow-up study at the University Hospital of Strasbourg to perform the non-specific bronchial hyperresponsiveness test to assess remission in patients diagnosed with occupational asthma and to compare baseline T2 biomarkers in remission and non remission patients.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| patients with occupational asthma | Other | Other: Measure of T2 biomarkers |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Age over 18
- Diagnosis of occupational asthma by specific inhalation challenge
- Exposure to sensitizing agent avoided or reduced
- Able to understand the aims and risks of the research and to give free and informed consent
- For women of childbearing age: effective contraception in progress.
Key exclusion criteria (4 listed)
- Impossibility of giving the subject informed information (subject in emergency situation, difficulties in understanding the subject)
- Subject under court protection
- Subject under guardianship or curatorship
- Pregnant or breast-feeding patient
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Measure of T2 biomarkersT2 Biomarkers are estimated via induced sputum: Sputum is induced through increasing concentrations from 0.9 or 3% to 4% and 5% of hypertonic solution. Assessment of nonspecific bronchial hyperresponsiveness is realized by metacholine challenge | Other | patients with occupational asthma |
Primary outcome
Remission of occupational asthma
Time frame: Day 1
Remission of occupational asthma is defined by absence of nonspecific bronchial hyperresponsiveness. Assessment of nonspecific bronchial hyperresponsiveness is realized by metacholine challenge
Comparison of TH2-type inflammation levels
Time frame: Day 1
To compare the level of Th2-type inflammation in sputum from patients in remission versus patients with persistent asthma.
1 secondary outcome
Remission of occupational rhinitis
Time frame: Day 1
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jun 2026.
Related trials for Asthma
RecruitingPhase 1
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
Asthma
RecruitingPhase 1
A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive
Asthma, Mild Asthma
RecruitingPhase 3
A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma
Asthma Control
Active, not recruitingPhase 2/3
Local Antibiotic Delivery for Community Acquired Pneumonia
Community Acquired Pneumonia (CAP)
RecruitingPhase 2
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
Asthma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Measure of T2 biomarkers in people with Asthma and Occupational Asthma, run by University Hospital, Strasbourg, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 23 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Remission of occupational asthma (time frame: Day 1). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jun 2026.